MARKET

SYBX

SYBX

Synlogic
NASDAQ
0.6735
-0.0298
-4.24%
Closed 16:00 12/07 EST
OPEN
0.7300
PREV CLOSE
0.7033
HIGH
0.7300
LOW
0.6607
VOLUME
55.91K
TURNOVER
26.43K
52 WEEK HIGH
2.820
52 WEEK LOW
0.5500
MARKET CAP
47.50M
P/E (TTM)
-0.7522
1D
5D
1M
3M
1Y
5Y
Will Synlogic (NASDAQ:SYBX) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 3d ago
BRIEF-Synlogic Says Realignment Is Estimated To Reduce Company's Workforce By About 25%
Reuters · 11/30 21:51
BRIEF-Synlogic Announces Synb1353 Achieves Proof Of Mechanism For Treatment Of Homocystinuria And Provides Business Update
Reuters · 11/30 21:40
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 11/30 21:32
Synlogic Announces SYNB1353 Achieves Proof Of Mechanism For Treatment Of Homocystinuria
Benzinga · 11/30 21:25
BRIEF-Synlogic Inc - On November 22, 2022, Unit Entered Into A Statement Of Work (The “Sow”) With Azzur Cleanrooms-On-Demand – Boston, Llc
Reuters · 11/23 12:12
'Synlogic Gets FDA Orphan Drug Designation For Live Biotherapeutic For Treatment Of Homocystinuria' - FDA
Benzinga · 11/22 20:51
BP To Rally Around 22%? Plus This Analyst Predicts $47 For YETI
Benzinga · 11/11 12:12
More
About SYBX
Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of synthetic biology therapeutics for the treatment of rare, infectious, and other diseases. Its pipeline includes its lead program in phenylketonuria (PKU). The Company's PKU program includes two development candidates, SYNB1618 and SYNB1934. SYNB1618 and SYNB1934 are orally administered, non-systemically absorbed drug candidates for PKU, which is a genetic disease caused by neurotoxic levels of the amino acid Phe. Its product pipeline includes SYNB1353 and SYNB8802. SYNB1353 is an orally administered, non-systemically absorbed live biotherapeutic drug candidate engineered to consume methionine in the gastrointestinal tract (GI) total homocysteine (tHcy) in homocystinuria (HCU) patients and allowing natural protein intake. SYNB8802 is a non-systemically absorbed drug candidate developed for the treatment of enteric hyperoxaluria.

Webull offers kinds of Synlogic Inc stock information, including NASDAQ:SYBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYBX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYBX stock methods without spending real money on the virtual paper trading platform.